CL2013000423A1 - Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno. - Google Patents
Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno.Info
- Publication number
- CL2013000423A1 CL2013000423A1 CL2013000423A CL2013000423A CL2013000423A1 CL 2013000423 A1 CL2013000423 A1 CL 2013000423A1 CL 2013000423 A CL2013000423 A CL 2013000423A CL 2013000423 A CL2013000423 A CL 2013000423A CL 2013000423 A1 CL2013000423 A1 CL 2013000423A1
- Authority
- CL
- Chile
- Prior art keywords
- active ingredient
- polyalkylene
- oxide
- anionic polysaccharide
- dosage form
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 4
- 229920001586 anionic polysaccharide Polymers 0.000 title abstract 4
- 150000004836 anionic polysaccharides Chemical class 0.000 title abstract 4
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title abstract 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 title abstract 2
- 229920001281 polyalkylene Polymers 0.000 title abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Forma de dosificación farmacéutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacárido aniónico y un óxido de polialquileno, en donde el ingrediente activo está presente en una matriz de liberación controlada comprendiendo el polisacárido aniónico y el óxido de polialquileno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10009124 | 2010-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000423A1 true CL2013000423A1 (es) | 2013-04-12 |
Family
ID=43897069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000423A CL2013000423A1 (es) | 2010-09-02 | 2013-02-12 | Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120059065A1 (es) |
| EP (1) | EP2611428B1 (es) |
| JP (1) | JP5925778B2 (es) |
| KR (1) | KR20130097201A (es) |
| CN (2) | CN103179956A (es) |
| AR (1) | AR082861A1 (es) |
| AU (1) | AU2011297954B2 (es) |
| BR (1) | BR112013005195A2 (es) |
| CA (1) | CA2808988C (es) |
| CL (1) | CL2013000423A1 (es) |
| CO (1) | CO6670598A2 (es) |
| EC (1) | ECSP13012473A (es) |
| ES (1) | ES2534847T3 (es) |
| IL (1) | IL224616A (es) |
| MX (1) | MX340427B (es) |
| NZ (1) | NZ607479A (es) |
| PE (1) | PE20131125A1 (es) |
| PL (1) | PL2611428T3 (es) |
| RU (1) | RU2013114411A (es) |
| TW (1) | TWI501788B (es) |
| WO (1) | WO2012028317A1 (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| ES2570454T3 (es) | 2003-03-26 | 2016-05-18 | Egalet Ltd | Sistema de liberación controlada de morfina |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032051A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| DE102004020220A1 (de) * | 2004-04-22 | 2005-11-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| DE102004032103A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102004032049A1 (de) * | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) * | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
| KR101690094B1 (ko) | 2008-05-09 | 2016-12-27 | 그뤼넨탈 게엠베하 | 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법 |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| ES2428938T3 (es) * | 2009-07-22 | 2013-11-12 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación |
| WO2011095314A2 (en) * | 2010-02-03 | 2011-08-11 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
| RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
| PL2611425T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Odporna na ingerencję postać dawki zawierająca polimer anionowy |
| PL2736495T3 (pl) | 2011-07-29 | 2018-01-31 | Gruenenthal Gmbh | Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku |
| HRP20171458T1 (hr) | 2011-07-29 | 2017-11-17 | Grünenthal GmbH | Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka |
| WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| LT2838512T (lt) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| CN104684548A (zh) | 2012-07-06 | 2015-06-03 | 埃格勒特有限责任公司 | 防止滥用的控释药物组合物 |
| WO2014011830A1 (en) | 2012-07-12 | 2014-01-16 | Mallinckrodt Llc | Extended release, abuse deterrent pharmaceutical compositions |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| AR096438A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| JP6539274B2 (ja) * | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| JP2017518980A (ja) | 2014-05-12 | 2017-07-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールを含む、改変防止即時放出カプセル製剤 |
| CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| CA2983640A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from different particles |
| KR20170139158A (ko) | 2015-04-24 | 2017-12-18 | 그뤼넨탈 게엠베하 | 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태 |
| CA2983648A1 (en) | 2015-04-24 | 2016-10-27 | Grunenthal Gmbh | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
| EP3285747A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
| US10183018B2 (en) | 2015-05-28 | 2019-01-22 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
| US11234974B2 (en) | 2015-05-28 | 2022-02-01 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
| WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| CN109789094A (zh) * | 2016-06-03 | 2019-05-21 | Jt药品公司 | κ-阿片类受体激动剂的持续释放组合物 |
| US20180028670A1 (en) * | 2016-08-01 | 2018-02-01 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polysaccharide |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612211A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Kontinuierliches verfahren zum tablettieren |
| US5900425A (en) * | 1995-05-02 | 1999-05-04 | Bayer Aktiengesellschaft | Pharmaceutical preparations having controlled release of active compound and processes for their preparation |
| US7141250B2 (en) | 2001-08-06 | 2006-11-28 | Euro-Celtique S.A. | Pharmaceutical formulation containing bittering agent |
| US6471120B1 (en) * | 2001-10-25 | 2002-10-29 | Colgate Palmolive Company | Easy opening handled carton |
| DE10252667A1 (de) | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| ES2570454T3 (es) * | 2003-03-26 | 2016-05-18 | Egalet Ltd | Sistema de liberación controlada de morfina |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) * | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| US8075872B2 (en) * | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| PT1842533E (pt) | 2003-08-06 | 2013-05-17 | Gruenenthal Gmbh | Forma de dosagem protegida contra abuso |
| DE10360792A1 (de) | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| JP5064209B2 (ja) | 2004-04-22 | 2012-10-31 | グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 乱用防止固体剤形を製造する方法 |
| EP1786403B1 (de) | 2004-07-01 | 2013-07-24 | Grünenthal GmbH | Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| PL1765303T5 (pl) * | 2004-07-01 | 2023-05-22 | Grünenthal GmbH | Tabletka doustna zabezpieczona przed nadużywaniem |
| EP1765298B1 (de) | 2004-07-01 | 2012-10-24 | Gruenenthal Gmbh | Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US20070190142A1 (en) | 2006-01-21 | 2007-08-16 | Abbott Gmbh & Co. Kg | Dosage forms for the delivery of drugs of abuse and related methods |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
| KR100970665B1 (ko) * | 2008-02-04 | 2010-07-15 | 삼일제약주식회사 | 알푸조신 또는 그의 염을 함유하는 서방성 정제 |
| CA2750400A1 (en) * | 2009-01-26 | 2010-07-29 | Egalet A/S | Controlled release formulations with continuous efficacy |
-
2011
- 2011-09-01 TW TW100131418A patent/TWI501788B/zh not_active IP Right Cessation
- 2011-09-01 MX MX2013002120A patent/MX340427B/es active IP Right Grant
- 2011-09-01 EP EP11761000.6A patent/EP2611428B1/en not_active Not-in-force
- 2011-09-01 KR KR1020137008511A patent/KR20130097201A/ko not_active Withdrawn
- 2011-09-01 CN CN2011800420125A patent/CN103179956A/zh active Pending
- 2011-09-01 BR BR112013005195A patent/BR112013005195A2/pt not_active IP Right Cessation
- 2011-09-01 CA CA2808988A patent/CA2808988C/en not_active Expired - Fee Related
- 2011-09-01 PE PE2013000330A patent/PE20131125A1/es active IP Right Grant
- 2011-09-01 AR ARP110103191A patent/AR082861A1/es unknown
- 2011-09-01 AU AU2011297954A patent/AU2011297954B2/en not_active Ceased
- 2011-09-01 JP JP2013526359A patent/JP5925778B2/ja not_active Expired - Fee Related
- 2011-09-01 RU RU2013114411/15A patent/RU2013114411A/ru not_active Application Discontinuation
- 2011-09-01 NZ NZ607479A patent/NZ607479A/en not_active IP Right Cessation
- 2011-09-01 US US13/223,358 patent/US20120059065A1/en not_active Abandoned
- 2011-09-01 ES ES11761000.6T patent/ES2534847T3/es active Active
- 2011-09-01 WO PCT/EP2011/004404 patent/WO2012028317A1/en not_active Ceased
- 2011-09-01 PL PL11761000T patent/PL2611428T3/pl unknown
- 2011-09-01 CN CN201710507176.XA patent/CN107308124A/zh active Pending
-
2013
- 2013-02-07 IL IL224616A patent/IL224616A/en active IP Right Grant
- 2013-02-11 CO CO13027448A patent/CO6670598A2/es unknown
- 2013-02-12 CL CL2013000423A patent/CL2013000423A1/es unknown
- 2013-03-01 EC ECSP13012473 patent/ECSP13012473A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013002120A (es) | 2013-04-03 |
| IL224616A (en) | 2017-06-29 |
| RU2013114411A (ru) | 2014-10-10 |
| JP5925778B2 (ja) | 2016-05-25 |
| ES2534847T3 (es) | 2015-04-29 |
| HK1184389A1 (en) | 2014-01-24 |
| CN107308124A (zh) | 2017-11-03 |
| CO6670598A2 (es) | 2013-05-15 |
| NZ607479A (en) | 2015-06-26 |
| EP2611428A1 (en) | 2013-07-10 |
| PE20131125A1 (es) | 2013-10-21 |
| PL2611428T3 (pl) | 2015-06-30 |
| AU2011297954B2 (en) | 2014-05-15 |
| CA2808988A1 (en) | 2012-03-08 |
| US20120059065A1 (en) | 2012-03-08 |
| TW201212954A (en) | 2012-04-01 |
| EP2611428B1 (en) | 2015-01-14 |
| AU2011297954A1 (en) | 2013-03-14 |
| CA2808988C (en) | 2018-05-01 |
| ECSP13012473A (es) | 2013-04-30 |
| KR20130097201A (ko) | 2013-09-02 |
| WO2012028317A1 (en) | 2012-03-08 |
| CN103179956A (zh) | 2013-06-26 |
| AR082861A1 (es) | 2013-01-16 |
| MX340427B (es) | 2016-07-08 |
| JP2013536809A (ja) | 2013-09-26 |
| TWI501788B (zh) | 2015-10-01 |
| BR112013005195A2 (pt) | 2016-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000423A1 (es) | Forma de dosificacion farmaceutica con resistencia a rompimiento de al menos 500 n, que contiene un ingrediente activo, un polisacarido anionico y un oxido de polialquileno, en donde el ingrediente activo esta presente en una matriz de liberacion controlada comprendiendo el polisacarido anionico y el oxido de polialquileno. | |
| CL2013000424A1 (es) | Forma de dosificacion farmaceutica resistente al rompimiento que comprende a) un ingrediente farmacologicamente activo, b) un polimero, c) un oxido de polialquileno, donde a) esta presente en una matriz de liberacion controlada que comprende b) y c). | |
| CL2013000437A1 (es) | Forma de dosificacion farmaceutica con resistencia a la rotura de al menos 500 n, que contiene un ingrediente activo, 5 al 70 % en peso de una sal inorganica, al menos 30% en peso de un oxido de polialquileno, en donde el ingrediente activo esta integrado en una matriz de liberacion controlada que comprende la sal inorganica y el oxido de polialquileno. | |
| MX2015016254A (es) | Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal. | |
| MX392839B (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| CR20140487A (es) | Peliculas de capas multiples capaces de liberar ingredientes activos por un periodo limitado de tiempo | |
| PE20140255A1 (es) | Tableta dispersable en forma oral | |
| CO6280466A2 (es) | Forma de dosificacion farmaceutica de liberacion controlada | |
| CL2011002968A1 (es) | Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion. | |
| CL2014000904A1 (es) | Forma de dosis farmaceutica oral resistente a la ruptura que comprende i) un ingrediente farmacologicamente activo, ii) un antagonista opioide y/o un agente repelente, iii) un oxido de polialquileno y iv) un polimero anionico. | |
| MX348491B (es) | Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco. | |
| MY173629A (en) | Dosage form | |
| CL2015002755A1 (es) | Composiciones antibióticas de ceftolozano. | |
| CL2014001585A1 (es) | Compuestos derivados de betulina; composicion farmaceutica; y el uso de los mismos en el tratamiento y prevencion de una infeccion por vih. | |
| AR091465A1 (es) | Una composicion farmaceutica que contiene acido nicotinico y/o nicotinamida y/o triptofano para influenciar positivamente la microbiota intestinal | |
| DOP2015000006A (es) | Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles | |
| BR112012024432A2 (pt) | composição farmacêutica de dissolução rápida | |
| EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| BR112014025041B8 (pt) | Composição farmacêutica | |
| CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
| MX2016003754A (es) | Una composicion farmaceutica estable que contiene amlodipina y valsartan. | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| CL2013000762A1 (es) | Composicion que comprende a) una particula de entrega de agente benefico que comprende poli-xiloglucano o poli-galactomanana y b) una mananasa. | |
| BR112014021068A2 (pt) | Inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor | |
| AR094289A1 (es) | Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol |